February 28, 2018 / 7:19 PM / 8 months ago

BRIEF-Sorrento Therapeutics' Unit Receives FDA Approval For Non-Opioid Ztlido

Feb 28 (Reuters) - Sorrento Therapeutics Inc:

* SORRENTO THERAPEUTICS SUBSIDIARY, SCILEX, RECEIVES US FDA APPROVAL FOR NON-OPIOID ZTLIDO™ (LIDOCAINE TOPICAL SYSTEM) 1.8% FOR PHN PAIN

* SORRENTO THERAPEUTICS SUBSIDIARY, SCILEX, RECEIVES US FDA APPROVAL FOR NON-OPIOID ZTLIDO™ (LIDOCAINE TOPICAL SYSTEM) 1.8% FOR PHN PAIN

* SORRENTO THERAPEUTICS INC - ‍INTEND TO EXPLORE EXPANSION OF ZTLIDO INTO ADDITIONAL INDICATIONS​

* SORRENTO THERAPEUTICS INC - ‍OBJECTIVE TO MAKE PRODUCT COMMERCIALLY AVAILABLE TO PATIENTS SOMETIME IN 2018​

* SORRENTO THERAPEUTICS - INTENDS TO HAVE SCILEX COMPLETE FINAL STEPS NECESSARY TO COMMERCIAL LAUNCH OF ZTLIDO IN U.S. Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below